

FULL TEXT LINKS

OXFORD
ACADEMIC

[Clinical Trial](#) [Pain Med.](#) 2012 Sep;13(9):1121-30. doi: 10.1111/j.1526-4637.2012.01432.x.
Epub 2012 Jul 30.

Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis

[Antonio Gatti](#)¹, [Marzia Lazzari](#), [Valentina Gianfelice](#), [Annarita Di Paolo](#), [Elisabetta Sabato](#),
[Alessandro Fabrizio Sabato](#)

Affiliations

PMID: 22845893 DOI: [10.1111/j.1526-4637.2012.01432.x](#)

Abstract

Objective: To assess the efficacy and safety of palmitoylethanolamide (PEA), an endogenous fatty acid amide belonging to the N-acylethanolamines family, in reducing pain severity in patients with pain associated to different pathological conditions.

Methods: This was an observational study conducted on 610 patients who were unable to effectively control chronic pain with standard therapies. PEA (600 mg) was administered twice daily for 3 weeks followed by single daily dosing for 4 weeks, in addition to standard analgesic therapies or as single therapy. The primary outcome measure was the mean score pain severity evaluated by the numeric rating scale. Safety was also evaluated.

Results: PEA treatment significantly decreased the mean score pain intensity evaluated in all patients who completed the study. The PEA effect was independent of the pain associated pathological condition. PEA-induced decrease of pain intensity was present also in patients without concomitant analgesic therapy. Importantly, PEA showed no adverse effects.

Conclusions: In this study, PEA was effective and safe in the management of chronic pain in different pathological conditions.

Wiley Periodicals, Inc.

[PubMed Disclaimer](#)

Comment in

[Emerging neuroprotective effects of N-palmitoylethanolamide besides its significant antinociceptive effects.](#)

Kapoor S.

Pain Med. 2013 May;14(5):773-4. doi: 10.1111/pme.12118. Epub 2013 Apr 12.

PMID: 23581707 No abstract available.

[Response to dr. Kapoor.](#)

Sabato AF.

Pain Med. 2013 May;14(5):775. doi: 10.1111/pme.12115. Epub 2013 Apr 24.

PMID: 23614877 No abstract available.

Related information

[MedGen](#)
[PubChem Compound](#)
[PubChem Compound \(MeSH Keyword\)](#)
[PubChem Substance](#)

LinkOut - more resources

Full Text Sources

[Ovid Technologies, Inc.](#)
[Silverchair Information Systems](#)
[Wiley](#)

Other Literature Sources

[The Lens - Patent Citations](#)

Medical

[MedlinePlus Health Information](#)